ImmuPharma (LON:IMM) Trading Down 5.6% – Should You Sell?

ImmuPharma plc (LON:IMM)’s stock price was down 5.6% during mid-day trading on Thursday . The company traded as low as GBX 2.42 ($0.03) and last traded at GBX 2.53 ($0.03). Approximately 685,774 shares were traded during mid-day trading, a decline of 91% from the average daily volume of 7,771,297 shares. The stock had previously closed at GBX 2.68 ($0.04).

ImmuPharma Price Performance

The firm’s 50-day simple moving average is GBX 2.76 and its 200 day simple moving average is GBX 2.83. The firm has a market capitalization of £10.34 million, a price-to-earnings ratio of -4.21 and a beta of 1.53.

ImmuPharma (LON:IMM) last issued its quarterly earnings results on Monday, May 19th. The company reported GBX (0.60) (($0.01)) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. As a group, research analysts predict that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

ImmuPharma Company Profile

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.